Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 5/20 | 0.54 |
| ▸ | MMP1 | P03956 | 2/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | GNG2 | P59768 | 1/20 | 0.52 |
| ▸ | GNB1 | P62873 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3645814 | 0.85 | NPC1 (0.66) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL8359448 | 0.85 | MMP9 (0.73) | KMT2AMEN1MMP9MMP1OPRL1 | |
| SCHEMBL3651398 | 0.83 | MEN1 (0.57) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL17478618 | 0.81 | NPC1 (0.60) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2176831 | 0.81 | NPC1 (1.00) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5848272 | 0.79 | MMP9 (0.71) | KMT2AMEN1MMP9MMP1OPRL1 | |
| SCHEMBL4745308 | 0.79 | NSD2 (0.49) | NPC1KMT2AMEN1MAPTHTT | |
| SCHEMBL19539216 | 0.78 | NPC1 (0.61) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5847897 | 0.77 | TERT (0.56) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL5848369 | 0.77 | NPC1 (0.55) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182950-B1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2017-07-19 | — | — | EP | disclosed |
| US-8759348-B2 | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| US-20100305065-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-12-02 | — | — | US | disclosed |
| CN-101795688-A | Use of 4- (pyrrolidin-1-yl) quinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LTD | 2010-08-04 | — | — | CN | disclosed |
| EP-2182950-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2010-05-12 | — | — | EP | disclosed |
| WO-2008142384-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305065-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | ARG1, LPO, CTSL | NPC1 1039/4885RAB9A 1593/4885KMT2A 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.